Industry expert Ralf Gärtner joins as SVP and Regional Manager to spearhead Vertex’s global operationsLONDON, Oct. 30, 2025 ...

Vertex, Inc. (NASDAQ:VERX) is one of the Best Beaten Down Growth Stocks to Buy According to Analysts. Wall Street has a mixed ...

Return on Assets (ROA): Vertex's financial strength is reflected in its exceptional ROA, which exceeds industry averages.

Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.

Analysts expect Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.35. Investors in Vertex Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of ...

Vertex should earn other important approvals through 2030 that could jolt its stock price. It's developing a treatment called ...

Vertex Minerals Ltd. ( ($AU:VTX) ) has issued an announcement. Vertex Minerals Limited has commenced underground ore production at the Reward Gold ...

Pennsylvania-based Conestoga Capital Advisors sold 855,435 Vertex shares for an estimated $24.8 million based on average ...

The growth for Vertex’s Journavax painkiller is just beginning to ramp up, given the potential size of the nonaddictive drug ...

Vertex Group appoints Krishna Gautam as Associate Managing Director for India operations. Focus on Vertex 2.0 transformation and digital innovation.

The new features are designed for companies training massive AI models, making it easier to manage complex workloads and keep ...

The bears will point out that Novo Nordisk is losing ground in the GLP-1 market to its most important competitor, Eli Lilly.